Search results | Galderma

Reports

Partnering Agreements with Galderma

This report provides all the information you require to better understand Galderma and its partnering interests and activities over the past seven years

Insights

Galderma

Galderma is a top pharmaceutical company based in Lausanne, Switzerland.

Galderma: M&A activity 2005-2013

Galderma has announced 4 M&A deals since 2009, with the lead deals being the acquisition of Q-Med.

Galderma: Partnering activity 2009-2014

Galderma is one of the top global pharmaceutical companies with a dermatology focus area.

Galderma – Derma Specialist prioritizing science driven licensing agreements

Galderma is one of the world’s largest dermatology and top 50 pharma companies.

Galderma: Company profile

Galderma, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Valeant Pharma & Galderma in a revised pharma alliances arrangement

Valeant Pharmaceuticals International has reached agreement on terms of a revised pharma alliances aesthetics arrangement with North American Galderma.

A review of the Top 50 Pharma companies of 2014

The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

Life Science M&A Deal Trends in Q1, 2014

With 85 deals announced, the first quarter of 2014 started strongly for life science M&A

LFB: M&A activity 2009 – 2014

LFB has announced only one M&A deal since 2009, with the acquisition of GTC Therapeutics

Events

Sorry, your search returned no results.


Deals

Bioventus signs a pharma deal with Galderma for Durolane

Bioventus has entered into pharma deal with Galderma to acquire the international assets for DUROLANE.

Valeant Pharma & Galderma in a revised pharma alliances arrangement

Valeant Pharmaceuticals International has reached agreement on terms of a revised pharma alliances aesthetics arrangement with North American Galderma.

AZ enters into collaborative R&D and licensing agreement with Galderma to develop new treatments for dermatological diseases

AstraZeneca and Galderma Pharma have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis.

Valeant sells its dermatology products for $1.4 billion

Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash.

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif